[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100132373":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":24,"responsibleParty":37,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":11,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pf-04531083",null,"To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects",[13],"Drug: PF-04531083",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","PF-04531083","solution. doses to be selected based upon safety\u002Ftolerability\u002FPK at preceeding dose",[9],[21],{"name":22,"affiliation":5,"role":23},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[25],{"facility":26,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Pfizer Investigational Site","Brussels","1070","Belgium","BE",{"type":32,"coordinates":33},"Point",[34,35],4.34878,50.85045,{"lat":35,"lon":34},{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":38,"oldOrganization":39},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100132373","to-investigate-the-safety-toleration-and-pharmacokinetics-of-single-oral-doses-of-pf-04531083-in-healthy-male-subjects-100132373",false,"NCT00992316","A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects","Inclusion Criteria:\n\n* young\n* healthy\n* male\n\nExclusion Criteria:\n\n* elderly\n* unhealthy\n* female",true,"MALE","21 Years","55 Years",{"count":51,"type":52},80,"ACTUAL","OBSERVATIONAL","The purpose of the study is to investigate the safety, toleration and pharmacokinetics of single oral doses of PF-04531083 in healthy male subjects.",[56],"Pain",[58],"Inflammatory pain","COMPLETED","2009-12-16",{"date":62,"type":63},"2009-12-17","ESTIMATED",{"date":65,"type":10},"2009-08",{"date":67,"type":52},"2009-12",{"name":5,"class":6},1]